Posted by Michael Wonder on 02 Nov 2022
Henlius' novel anti-PD-1 mAb Hansizhuang (serplulimab) receives NMPA approval for the treatment of sqNSCLC
1 November 2022 - Shanghai Henlius Biotech announced that its first self-developed innovative anti-PD-1 monoclonal antibody Hansizhuang (serplulimab), in combination with carboplatin and albumin-bound paclitaxel for the first-line treatment of unresectable locally advanced or metastatic squamous non-small-cell lung cancer, has been approved by the NMPA, providing an alternative treatment option for patients.
Hansizhuang had already been approved for the treatment of microsatellite instability-high solid tumours, and it covers a wide variety of indications to benefit a broader population of patients.
